These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12196362)

  • 1. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation.
    Bierman PJ; Lynch JC; Bociek RG; Whalen VL; Kessinger A; Vose JM; Armitage JO
    Ann Oncol; 2002 Sep; 13(9):1370-7. PubMed ID: 12196362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
    Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R
    Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.
    Hasenclever D; Diehl V
    N Engl J Med; 1998 Nov; 339(21):1506-14. PubMed ID: 9819449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
    Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
    Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices.
    Lieskovsky YE; Donaldson SS; Torres MA; Wong RM; Amylon MD; Link MP; Agarwal R
    J Clin Oncol; 2004 Nov; 22(22):4532-40. PubMed ID: 15542804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.
    Josting A; Franklin J; May M; Koch P; Beykirch MK; Heinz J; Rudolph C; Diehl V; Engert A
    J Clin Oncol; 2002 Jan; 20(1):221-30. PubMed ID: 11773173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.
    Gutierrez-Delgado F; Holmberg L; Hooper H; Petersdorf S; Press O; Maziarz R; Maloney D; Chauncey T; Appelbaum F; Bensinger W
    Bone Marrow Transplant; 2003 Aug; 32(3):279-85. PubMed ID: 12858199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party.
    Sweetenham JW; Carella AM; Taghipour G; Cunningham D; Marcus R; Della Volpe A; Linch DC; Schmitz N; Goldstone AH
    J Clin Oncol; 1999 Oct; 17(10):3101-9. PubMed ID: 10506605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
    Hahn T; Benekli M; Wong C; Moysich KB; Hyland A; Michalek AM; Alam A; Baer MR; Bambach B; Czuczman MS; Wetzler M; Becker JL; McCarthy PL
    Bone Marrow Transplant; 2005 Mar; 35(6):557-66. PubMed ID: 15665852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Factors and a New Prognostic Index Model for Children and Adolescents with Hodgkin's Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation: A Multicenter Study of the Turkish Pediatric Bone Marrow Transplantation Study Group.
    Kesik V; Ataş E; Karakükcü M; Aksoylar S; Erbey F; Taçyıldız N; Küpesiz A; Öniz H; Ünal E; Kansoy S; Öztürk G; Elli M; Kaya Z; Ünal E; Hazar V; Yılmaz Bengoa Ş; Karasu G; Atay D; Dağdemir A; Ören H; Koçak Ü; Yeşilipek MA
    Turk J Haematol; 2016 Dec; 33(4):265-272. PubMed ID: 27094103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
    Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
    Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
    J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.
    Popat U; Hosing C; Saliba RM; Anderlini P; van Besien K; Przepiorka D; Khouri IF; Gajewski J; Claxton D; Giralt S; Rodriguez M; Romaguera J; Hagemeister F; Ha C; Cox J; Cabanillas F; Andersson BS; Champlin RE
    Bone Marrow Transplant; 2004 May; 33(10):1015-23. PubMed ID: 15048145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and prognostic factors in Chinese patients with Hodgkin's lymphoma.
    Zhu YJ; Sun YL; Xia Y; Jiang WQ; Huang JJ; Huang HQ; Lin TY; Guan ZZ; Li ZM
    Med Oncol; 2012 Jun; 29(2):1127-33. PubMed ID: 21390515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.